{"id":752089,"date":"2023-04-27T10:06:03","date_gmt":"2023-04-27T14:06:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/"},"modified":"2023-04-27T10:06:03","modified_gmt":"2023-04-27T14:06:03","slug":"mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/","title":{"rendered":"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results"},"content":{"rendered":"
\n

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2023 financial results before the market opens on Thursday, May 11, 2023. Members of the MiNK leadership team will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.<\/p>\n

\n Conference Call<\/strong>\n <\/p>\n

Dial in numbers: 646-307-1963 (USA-NY), 800-715-9871 (USA & Canada)<\/p>\n

Conference ID: 8437743<\/p>\n

\n Webcast<\/strong>\n <\/p>\n

A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company\u2019s website at https:\/\/investor.minktherapeutics.com\/events-and-presentations<\/a> and via https:\/\/edge.media-server.com\/mmc\/p\/4c4qmbci<\/a>.<\/p>\n

\n About MiNK Therapeutics <\/strong>\n <\/p>\n

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https:\/\/minktherapeutics.com\/<\/a>. Follow us on Twitter @MiNK_iNKT.<\/p>\n

\n Contact<\/strong>\n <\/p>\n

Alexa Buffa
781-674-4428
communications@minktherapeutics.com<\/p>\n

Investor relations
Zack Armen
917-362-1370
investor@minktherapeutics.com<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2023 financial results before the market opens on Thursday, May 11, 2023. Members of the MiNK leadership team will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial in numbers: 646-307-1963 (USA-NY), 800-715-9871 (USA & Canada) Conference ID: 8437743 Webcast A live webcast and replay of the conference call will be accessible from the … <\/p>\n

Continue reading “MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-752089","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2023 financial results before the market opens on Thursday, May 11, 2023. Members of the MiNK leadership team will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial in numbers: 646-307-1963 (USA-NY), 800-715-9871 (USA & Canada) Conference ID: 8437743 Webcast A live webcast and replay of the conference call will be accessible from the … Continue reading "MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-27T14:06:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEzNyM1NTU4ODkxIzIyMjMyMTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results\",\"datePublished\":\"2023-04-27T14:06:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/\"},\"wordCount\":247,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEzNyM1NTU4ODkxIzIyMjMyMTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/\",\"name\":\"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEzNyM1NTU4ODkxIzIyMjMyMTE=\",\"datePublished\":\"2023-04-27T14:06:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEzNyM1NTU4ODkxIzIyMjMyMTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNjEzNyM1NTU4ODkxIzIyMjMyMTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results - Market Newsdesk","og_description":"NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2023 financial results before the market opens on Thursday, May 11, 2023. Members of the MiNK leadership team will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial in numbers: 646-307-1963 (USA-NY), 800-715-9871 (USA & Canada) Conference ID: 8437743 Webcast A live webcast and replay of the conference call will be accessible from the … Continue reading \"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-27T14:06:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEzNyM1NTU4ODkxIzIyMjMyMTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results","datePublished":"2023-04-27T14:06:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/"},"wordCount":247,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEzNyM1NTU4ODkxIzIyMjMyMTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/","name":"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEzNyM1NTU4ODkxIzIyMjMyMTE=","datePublished":"2023-04-27T14:06:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEzNyM1NTU4ODkxIzIyMjMyMTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNjEzNyM1NTU4ODkxIzIyMjMyMTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mink-therapeutics-to-report-first-quarter-2023-corporate-update-and-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752089","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=752089"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752089\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=752089"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=752089"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=752089"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}